Dragon Pharma Sem

aglutide, a potent once-weekly GLP-1 RA, offers significant reductions in HbA1c, body weight, and systolic blood pressure.

However, it is associated with an increased incidence of gastrointestinal adverse events. Results for pancreatitis and retinopathy require further assessment in post-approval pharmacovigilance studies.

Highlights:

1. Semaglutide as an appetite suppressant and weight loss agent.
2. Semaglutide in prediabetes.

A phase 3, double-blind, randomized, controlled trial compared semaglutide with placebo, along with lifestyle changes, in overweight or obese adults without diabetes.

Participants (n=1961) were assigned to receive weekly subcutaneous semaglutide (2.4 mg, gradually increased) or placebo for 68 weeks. With both groups undergoing counseling interventions involving diet and exercise. Coprimary endpoints were the percentage change in body weight and weight reduction of 5% or more.

Semaglutide Results:

Efficacy: By week 68, mean weight declined significantly more with semaglutide than with placebo (14.9% vs. 2.4%; estimated difference, -12.4 percentage points; 95% CI, -13.4 to -11.5).

Additionally, a higher proportion of participants in the semaglutide group achieved weight loss of 5% or more (86.4% vs. 31.5%).

Safety

Adverse events, mainly gastrointestinal, were mostly mild to moderate, leading to treatment discontinuation in 7.0% of the semaglutide group and 3.1% of the placebo group. Serious adverse events, primarily gastrointestinal and hepatobiliary events, were reported more frequently with semaglutide.

Weekly injections of semaglutide (2.4 mg) added to lifestyle changes resulted in clinically relevant weight loss for overweight or obese adults without diabetes.

Where to Buy Dragon Pharma Semaglutide?

Semaglutide is available in many pharmacies worldwide under different brand names. Buy Dragon Pharma Semaglutide from official supplier - Dragon Pharma Store.